NEXD

NexD is a South Korean biotechnology company specializing in the development of advanced drug delivery systems (DDS) to create long-acting injectable formulations. The company's proprietary NexD-DDS platform utilizes microsphere technology to extend the release of existing drugs, improving patient compliance and therapeutic efficacy. Their lead programs include long-acting versions of semaglutide for obesity and diabetes, dutasteride for hair loss, and donepezil for Alzheimer's disease. By focusing on high-demand therapeutic areas, NexD aims to provide value-added medicines that reduce dosing frequency from daily or weekly to monthly or quarterly. The company is positioned as a Bio-Better developer, leveraging proven molecules to minimize clinical risk while maximizing patient convenience.